Enabling Technology Marketing Intern

Transient troubles shake up European market. by Mike Evers on September 15, 2026 The orthopedic market in Western Europe has shifted significantly over the last few years. In 2024, orthopedic procedure volumes were still rebounding from the disruption of the pandemic and Europe was driving significant growth. "The volumes outside the U.S. remain very strong, in particular in Europe," said Zimmer Biomet CEO Ivan Tornos in mid-2024. "Within Europe there is a prominent backlog. So, market dynamics are very healthy, more in EMEA than APAC, but very healthy overall." That strength persisted through much of 2025. Stryker called Europe a "growth engine" and said it had a huge opportunity to increase international penetration of the best-performing U.S. products. Both Medacta and Medartis saw their EMEA sales take off in the wake of the pandemic. CONMED's growth rate in EMEA has outpaced its growth rate in the United States over the last 10 years. Enovis used its aggressive M&A strategy to rapidly globalize and surpass $1 billion in annual reconstructive sales. In recent years, the company purchased European players like Mathys, Novastep and LimaCorporate. Today, international sales make up 53% of Enovis' total recon revenue. However, the European market has slowed significantly in 2026. "I would say it's more weighted to the transient," said Enovis CEO Damien McDonald. "Strikes, fires, heat waves, all of those things, we believe, are transient. Ultimately, you keep the patient in the funnel. The only thing for me is sentiment as the war in the Middle East continues, and what does that do as people reorient funding towards military spend versus health care. We haven't seen any of that read through, but that's the watch out." Below, Orthoworld'll take a look at some of the factors Mr. McDonald mentioned and how they're impacting the Western European orthopedic market. Strikes limit procedure capacity and extend wait times. European healthcare strikes and labor actions have come to a head due to wage disputes, staff shortages, burnout and rapidly rising demand. These factors are pushing up against government efforts to control healthcare costs. The U.K. experienced repeated resident doctor strikes, with the most recent action taking place in April 2026. The walkout cost the country an estimated £3 billion over the course of three years due to canceled procedures, rescheduling, overtime and higher-cost replacement staff. The procedure bottleneck in the U.K. goes beyond labor unrest. Highly specialized clinical roles are struggling to meet demand. A report from the Royal College of Anaesthetists estimated that staffing shortages were preventing 1.5 million procedures annually. Healthcare strikes in Spain are more variable and diffused across regions. In Rioja, for instance, strikes in 2026 caused the suspension of 39,000 consultations and 1,200 surgical procedures. More than 8,500 patients were awaiting surgery, and the average surgical wait time grew to 86 days. Orthopedic procedures are predominantly elective, and are therefore easily postponed. But, as Orthoworld saw during the pandemic, many of these patients remain in the funnel and eventually have their surgery done. However, not every orthopedic company is robust enough to withstand an extended downturn in procedure volume. Ongoing disruption in a market like Europe could have strategic implications for even the largest players. The Iran war impact is far-reaching. One of the most prevalent indirect impacts from the Iran war is the shock to energy prices. Oil prices are well above $100 per barrel in September of 2026. European natural gas prices have surged amid fears about Middle Eastern exports and winter storage. Increasing energy prices could further tax hospitals with already limited budget flexibility. The conflict has disrupted trade routes and increased transportation costs, which compound already inflated energy prices. In March, the World Health Organization warned that supply chain disruption can limit access to essential medicines and medical supplies. For orthopedic companies, the risk is spread across a wide array of categories including but not limited to polymer components, packaging, electronic components for robotics and navigation, as well as coatings and specialty materials. An increasingly unstable geopolitical climate has also caused defense spending in Europe to compete with limited fiscal space. There isn't a one-to-one trade-off between defense and healthcare, but Orthoworld is seeing some countries constrain healthcare spending while expanding defense spending. France's 2026 government budget included £5 billion in healthcare-related reductions or cost-containment measures, including higher deductibles, more oversight of long-term illness coverage and reductions in hospital operation costs. Per Le Monde, French public hospitals were already carrying a £3 billion deficit. Concurrently, France's 2026 fiscal plan called for £6.5 billion in additional defense spending. In the wake of Russia's invasion of Ukraine, Finland plans to increase defense spending despite ongoing austerity measures. The country intends to further cut healthcare and social services to reduce the fiscal deficit and rising public debt. Reuters reported that the healthcare and social services reductions were part of the fiscal consolidation program to facilitate increased defense spending. The picture in the U.K. and Germany is more nuanced. Defense spending is increasing, but not directly at the expense of healthcare. However, the expanded footprint of defense in budgets can crowd out other services and apply more pressure to patients as adjacent social services are reduced. The road ahead. Orthoworld agree with Mr. McDonald that these troubles are likely transient. Or, at least, some of them are. Fiscal policy isn't something that can change overnight. Orthoworld learned during the period from 2020 to 2022 that orthopedic patients tend to be sticky. They defer procedures for a long time, but ultimately, they return since they're not going to get better otherwise. Companies that can demonstrate greater efficiency in the operation room and provide better value-based solutions will have a strategic advantage in the European market of the near future. Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Zimmer Biomet announces Americas leadership promotions to accelerate commercial transformation. Sep 08, 2026, 16:30 ET Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas - Robotics, Technology and Data WARSAW, Ind., Sept. 8, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced leadership appointments designed to streamline its Americas and Global Business Group organizations for greater focus and agility. Effective October 1, Gary Campbell will be promoted to President, Americas, and Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery. The company also announced the promotion of Bradley Kessler to President, Americas - Robotics, Technology and Data. Campbell, Hatcher and Kessler will report directly to Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "We talk often about our People and Culture strategic imperative to have the right talent, in the right roles, at the right times," said Tornos. "These well-deserved promotions do exactly that, while helping to accelerate our U.S. go-to-market transformation and sharpen ownership of our most important commercial priorities. Gary, Brian and Brad are seasoned operators and proven Zimmer Biomet leaders with deep experience in the businesses and markets they will now lead. Their promotions reinforce my strong confidence in both our 2026 outlook and our growth potential in 2027 and beyond." As part of this restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company on September 30, 2026, following a transition period. Tornos added, "On behalf of the entire Zimmer Biomet team, I want to thank Kevin for his leadership and contributions to our company. We wish him all the best in his next chapter." 2026 Outlook Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026. About Gary Campbell As President, Americas, Campbell will be responsible for commercial strategy and execution across the United States, Canada and Latin America. He will continue to lead the evolution of the company's U.S. go-to-market model, building a specialized and dedicated organization designed to increase productivity and accelerate growth. Campbell has served as Zimmer Biomet's vice president and general manager, Orthopedics - North America since September 2024. Since joining the company in 2019, Campbell has held multiple commercial leadership roles of increasing responsibility. Previously, Campbell served in several sales and marketing roles at Enovis. He holds a bachelor's degree from Texas State University. About Brian Hatcher As President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead global portfolio strategy and execution across most of the company's businesses, expanding his current remit to include Global Knees and Hips. He will continue to play an integral role in the company's innovation and diversification strategy, including delivering organic and inorganic opportunities in higher growth markets. Lou Galrao, President of Reconstruction (Knees and Hips), will report to Hatcher. During his 16-year career with Zimmer Biomet, Hatcher has held multiple roles in research, marketing, general management and business leadership. He was named to his first Global President role in 2021 and currently serves as Zimmer Biomet's President of S.E.T. and CMFT. Hatcher began his medical technology career with roles at OrbusNeich and later Medtronic. He holds a bachelor's degree in chemistry and a Ph.D. in biomedical engineering, both from the University of Florida. About Brad Kessler As President, Americas - Robotics, Technology and Data, Kessler will be responsible for driving commercial strategy, growth and adoption of the company's broad portfolio of robotics, digital and technology solutions in the Americas, as well as its global service and capital solutions contracting business. Under Kessler's leadership, the company will accelerate the expansion of its specialized robotics salesforce in advance of the highly anticipated launch of the Monogram next-generation orthopedic robot, which is expected in 2027. Kessler brings to the role more than two decades of commercial experience in orthopedics. Currently vice president and general manager, Robotics, Technology and Data Solutions, Kessler has held multiple commercial leadership roles of increasing responsibility since he joined Zimmer Biomet in 2015. Prior to joining Zimmer Biomet, Kessler spent nearly 10 years in sales at Stryker. He holds a bachelor's degree from Texas A&M University and an Executive MBA from the Cox School of Business at Southern Methodist University. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, outlook, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission ("SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: Media Troy Kirkpatrick 614-284-1926 [email protected] Kirsten Fallon 781-779-5561 [email protected] | Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] | SOURCE Zimmer Biomet Holdings, Inc.